Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900003 · ClinicalTrials.gov registry record
Studying Biomarkers in Patients With Pancreatic Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 53
- Enrollment target
NCT00900003: Completed study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT00900003 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900003 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with pancreatic cancer.
Primary Outcome
Examine the location of BRCA1 in the cells and determine if this location predicts patient response to the chemotherapy drugs given
Interventions
- OTHER laboratory biomarker analysis
- GENETIC protein analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-05 |
| Est. Completion | 2013-03 |
What the finished NCT00900003 record still lists
NCT00900003 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00900003 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00900003 about?
NCT00900003 is a clinical study titled "Studying Biomarkers in Patients With Pancreatic Cancer". RATIONALE: Studying samples of tissue in the laboratory from patients with cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients wit...
What is the current status of trial NCT00900003?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2007-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00900003?
The interventions under investigation include: laboratory biomarker analysis (OTHER), protein analysis (GENETIC).
Who is sponsoring clinical trial NCT00900003?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia